HRP20020120A2 - Torsemide polymorphs - Google Patents

Torsemide polymorphs Download PDF

Info

Publication number
HRP20020120A2
HRP20020120A2 HR20020120A HRP20020120A HRP20020120A2 HR P20020120 A2 HRP20020120 A2 HR P20020120A2 HR 20020120 A HR20020120 A HR 20020120A HR P20020120 A HRP20020120 A HR P20020120A HR P20020120 A2 HRP20020120 A2 HR P20020120A2
Authority
HR
Croatia
Prior art keywords
torsemide
modification
solvent
mixture
preparation
Prior art date
Application number
HR20020120A
Other languages
English (en)
Croatian (hr)
Inventor
Judith Aronhime
David Leonov
Marko Kordova
Anchel Schwartz
Ben-Zion Dolitzky
Original Assignee
Teva Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma filed Critical Teva Pharma
Publication of HRP20020120A2 publication Critical patent/HRP20020120A2/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Details Of Garments (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
  • Pressure Welding/Diffusion-Bonding (AREA)
HR20020120A 1999-08-11 2000-08-11 Torsemide polymorphs HRP20020120A2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14830599P 1999-08-11 1999-08-11
US18312700P 2000-02-17 2000-02-17
US21527300P 2000-06-30 2000-06-30

Publications (1)

Publication Number Publication Date
HRP20020120A2 true HRP20020120A2 (en) 2003-10-31

Family

ID=27386674

Family Applications (1)

Application Number Title Priority Date Filing Date
HR20020120A HRP20020120A2 (en) 1999-08-11 2000-08-11 Torsemide polymorphs

Country Status (24)

Country Link
US (1) US6465496B1 (enExample)
EP (1) EP1207880A4 (enExample)
JP (1) JP2003527319A (enExample)
KR (1) KR20020025217A (enExample)
CN (1) CN1378448A (enExample)
AU (1) AU781461C (enExample)
BG (1) BG106400A (enExample)
CA (1) CA2379322A1 (enExample)
CZ (1) CZ2002404A3 (enExample)
DE (1) DE00957398T1 (enExample)
ES (1) ES2204354T1 (enExample)
HK (1) HK1046636A1 (enExample)
HR (1) HRP20020120A2 (enExample)
HU (1) HUP0204318A3 (enExample)
IL (1) IL148031A0 (enExample)
LT (1) LT5004B (enExample)
MX (1) MXPA02001369A (enExample)
NO (1) NO20020622L (enExample)
PL (1) PL354262A1 (enExample)
SI (1) SI20816A (enExample)
SK (1) SK1912002A3 (enExample)
TR (1) TR200200353T2 (enExample)
WO (1) WO2001010441A1 (enExample)
YU (1) YU9502A (enExample)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SK11632003A3 (sk) * 2000-02-17 2004-04-06 Teva Pharmaceutical Industries Ltd. Stabilný farmaceutický prípravok obsahujúci modifikáciu II torsemidu
DE10013289A1 (de) * 2000-03-17 2001-09-20 Knoll Ag Torasemid enthaltende pharmazeutische Zubereitungen
HRP20000162B1 (en) 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
US20030022921A1 (en) * 2001-02-21 2003-01-30 Minutza Leibovici Stable pharmaceutical formulation comprising torsemide modification II
EP1397343A1 (en) 2001-05-31 2004-03-17 Orion Corporation Fermion Process for preparing sertraline hydrochloride polymorphic form ii
IN192178B (enExample) 2001-08-03 2004-03-06 Ranbaxy Lab
US20030119882A1 (en) * 2001-10-22 2003-06-26 Markus Maegerlein Solid pharmaceutical composition containing torasemide
ITMI20020639A1 (it) * 2002-03-27 2003-09-29 Cosma S P A Composizioni farmaceutiche comprendenti come principio attivo 1-isopropil-3°(4-m-toluidino-3-pridil)sulfonil!-urea
HRP20020603B1 (en) * 2002-07-19 2008-11-30 Pliva D.D. New process for the preparation of modification i n-(1-methylethylaminocarbonyl)-4-(3-methylphenylamino)-3-pyridinesulfonamide
CA2424644A1 (en) * 2003-04-07 2004-10-07 David John Mckenzie Preparation of torasemide
ES2244324B1 (es) * 2004-03-25 2006-11-16 Ferrer Internacional, S.A. Composiciones diureticas de liberacion prolongada.
AT500576B1 (de) * 2004-07-28 2006-11-15 Sanochemia Pharmazeutika Ag Verfahren zur reindarstellung von kristallformen von torsemid
KR100845383B1 (ko) * 2004-12-24 2008-07-09 일동제약주식회사 토르세미드 변형체(ⅰ)의 제조방법
US20070122483A1 (en) * 2005-11-29 2007-05-31 Sharon Myers Fluocinolone acetonide drug substance polymorphic interconversion
AU2014348523B2 (en) 2013-11-15 2019-01-03 Akebia Therapeutics, Inc. Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
CN105949115A (zh) * 2016-05-26 2016-09-21 南京正科医药股份有限公司 一种新晶型托拉塞米
CN115417810B (zh) * 2022-09-22 2023-10-10 南京正科医药股份有限公司 一种托拉塞米晶型ⅰ的精制方法
CN117486789A (zh) * 2023-12-29 2024-02-02 江西中医药大学 一种托拉塞米共晶盐及其制备方法和应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US30633A (en) 1860-11-13 Improvement in fire-escapes
US34672A (en) 1862-03-18 Improved convertible boat, bridge, and tent
GB1477664A (en) 1974-04-17 1977-06-22 Christiaens Sa A Pyridine derivatives
US4055650A (en) 1974-04-17 1977-10-25 A. Christiaens Societe Anonyme Certain 4-phenoxy(or phenylthio)-3-n-acylated-sulfonamido-pyridines
DE3529529A1 (de) * 1985-08-17 1987-02-19 Boehringer Mannheim Gmbh Verfahren zur herstellung einer stabilen modifikation von torasemid
DE3623620A1 (de) 1986-07-12 1988-01-21 Boehringer Mannheim Gmbh Spritzfertige, waessrige, alkalische injektionsloesungen von torasemid und verfahren zu ihrer herstellung
HRP980532B1 (en) * 1998-10-02 2005-06-30 Pliva Novel crystalline torasemide modification
US5914336A (en) * 1998-06-02 1999-06-22 Boehringer Mannheim Gmbh Method of controlling the serum solubility of orally administered torasemide and composition relating thereto
US6166045A (en) * 1998-06-02 2000-12-26 Roche Diagnostics Gmbh Torasemide of modification III
HRP20000162B1 (en) * 2000-03-20 2004-06-30 Pliva D D Amorphous torasemide modification
CA2403382A1 (en) * 2000-03-20 2001-09-27 Teva Pharmaceutical Industries Ltd. Novel processes for preparing torsemide intermediate
HRP20000328A2 (en) * 2000-05-19 2002-02-28 Pliva Farmaceutska Ind Dionik Novel polymorph v of torasemide

Also Published As

Publication number Publication date
ES2204354T1 (es) 2004-05-01
US6465496B1 (en) 2002-10-15
HUP0204318A3 (en) 2005-03-29
CA2379322A1 (en) 2001-02-15
JP2003527319A (ja) 2003-09-16
NO20020622L (no) 2002-03-14
IL148031A0 (en) 2002-09-12
MXPA02001369A (es) 2005-08-26
HK1046636A1 (zh) 2003-01-24
PL354262A1 (en) 2003-12-29
NO20020622D0 (no) 2002-02-08
CZ2002404A3 (cs) 2002-06-12
EP1207880A1 (en) 2002-05-29
AU781461B2 (en) 2005-05-26
AU781461C (en) 2006-02-23
CN1378448A (zh) 2002-11-06
SK1912002A3 (en) 2002-07-02
EP1207880A4 (en) 2004-09-01
WO2001010441A1 (en) 2001-02-15
LT2002017A (en) 2002-11-25
HUP0204318A2 (en) 2003-05-28
DE00957398T1 (de) 2004-04-15
TR200200353T2 (tr) 2002-06-21
LT5004B (lt) 2003-03-25
SI20816A (sl) 2002-08-31
BG106400A (en) 2002-08-30
KR20020025217A (ko) 2002-04-03
YU9502A (sh) 2005-06-10
AU6902600A (en) 2001-03-05

Similar Documents

Publication Publication Date Title
HRP20020120A2 (en) Torsemide polymorphs
AU2002366383B2 (en) Polymorphs of clopidogrel hydrogensulfate
CA2304702C (en) Oral compositions of levosimendan
US8329912B2 (en) Solid forms of 2-chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine
JP2006249105A (ja) ゾルピデムヘミタートレイト
WO2007109799A2 (en) Polymorphs of eszopiclone malate
CZ20022000A3 (cs) Způsoby přípravy a nová krystalická forma leflunomidu
WO2004085393A1 (en) Novel crystalline forms of tegaserod maleate
WO2014193887A1 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihydroimidazo[4,5 d]fy rrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
US20070260068A1 (en) Method for the Preparation of Crystal Forms of Torsemide in a Pure State
EP3004104A1 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
EP1604986A1 (en) Novel crystal of n- 3-(formylamino)-4-oxo-6-phenoxy-4h-crome ne-7-yl methanesulfonamide
WO2014193865A1 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihydroimidazo[4,5- d]fy rrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
ZA200200967B (en) Tomsemide Polymorphs.
EP1713769B1 (en) Amorphous tamsulosin hydrochloride
CA2596754A1 (en) Crystalline 1h-imidazo[4,5-b]pyridin-5-amine,7-[5-[(cyclohexylmethylamino)-methyl]-1h-indol-2-yl]-2-methyl, sulfate (1:1), trihydrate and its uses for the treatment of inflammatory, autoimmune and proliferative diseases and disorders
WO2004076406A2 (en) Losartan potassium polymorphs and process for the preparation thereof
EP2109613A2 (en) Polymorphs of eszopiclone malate
WO2006109318A1 (en) Novel polymorph of 3-hydroxy-3-(3’-sulfamyl-4’-chlorophenyl)phthalimidine

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
ODRP Renewal fee for the maintenance of a patent

Payment date: 20060721

Year of fee payment: 7

OBST Application withdrawn